Scarica l'app Stockscreener
105.92
4.21%
-4.65
Dopo l'orario di chiusura:
106.41
0.49
+0.46%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$110.57
Aprire:
$109.74
Volume 24 ore:
2.30M
Relative Volume:
1.02
Capitalizzazione di mercato:
$20.79B
Reddito:
$4.58B
Utile/perdita netta:
$870.87M
Rapporto P/E:
24.08
EPS:
4.3988
Flusso di cassa netto:
$945.58M
1 W Prestazione:
+7.24%
1M Prestazione:
+9.53%
6M Prestazione:
+56.52%
1 anno Prestazione:
+44.84%
Intervallo 1D:
$104.69
$110.09
Intervallo di 1 settimana:
$97.94
$112.29
Portata 52W:
$53.56
$112.29
Incyte Corp Stock (INCY) Company Profile
Nome
Incyte Corp
Settore
Industria
Telefono
(302) 498-6700
Indirizzo
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Confronta INCY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
105.92 | 21.71B | 4.58B | 870.87M | 945.58M | 4.3988 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-08 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-11-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2025-10-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | Iniziato | Barclays | Overweight |
| 2025-06-16 | Aggiornamento | Stifel | Hold → Buy |
| 2025-03-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-03-18 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | Iniziato | UBS | Neutral |
| 2024-10-29 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-01 | Iniziato | Wolfe Research | Outperform |
| 2024-09-18 | Downgrade | Truist | Buy → Hold |
| 2024-07-02 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | Iniziato | Deutsche Bank | Hold |
| 2024-04-23 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-02-23 | Iniziato | Jefferies | Buy |
| 2024-02-14 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-11-21 | Downgrade | Goldman | Buy → Neutral |
| 2023-07-25 | Iniziato | Citigroup | Buy |
| 2023-05-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-04-10 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | Iniziato | Piper Sandler | Overweight |
| 2022-08-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-08-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-07-28 | Iniziato | Wells Fargo | Equal Weight |
| 2022-02-09 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-07-20 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-02-10 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | Iniziato | Truist | Buy |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-06-16 | Iniziato | The Benchmark Company | Hold |
| 2020-05-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | Ripresa | William Blair | Outperform |
| 2020-03-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | Ripresa | BofA/Merrill | Neutral |
| 2020-01-03 | Reiterato | BMO Capital Markets | Market Perform |
| 2020-01-03 | Downgrade | Mizuho | Buy → Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-10-03 | Iniziato | Mizuho | Buy |
| 2019-09-12 | Iniziato | BMO Capital Markets | Market Perform |
| 2019-09-05 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-09-05 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-05-21 | Iniziato | Credit Suisse | Neutral |
| 2019-05-03 | Downgrade | Barclays | Overweight → Equal Weight |
| 2019-04-11 | Iniziato | Stifel | Hold |
| 2019-04-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | Aggiornamento | William Blair | Mkt Perform → Outperform |
Mostra tutto
Incyte Corp Borsa (INCY) Ultime notizie
Can Incyte Corporation stock reach $100 price targetExit Point & Scalable Portfolio Growth Methods - ulpravda.ru
Can Incyte Corporation stock beat market expectations this quarter2025 Macro Impact & Low Volatility Stock Recommendations - ulpravda.ru
Incyte jumps amid takeover speculation - MSN
Incyte Corp. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Incyte Corp EVP & Chief Medical Officer Sells 15,634 Shares - TradingView — Track All Markets
Incyte (INCY) Stock Is Up, What You Need To Know - Finviz
Incyte eyes first-line nod for Tafasitamab in aggressive lymphoma - Indian Pharma Post
Incyte stock hits 52-week high at $109.38 - Investing.com
INCY: Morgan Stanley Boosts Price Target to $94 in Latest Analys - GuruFocus
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Dow, S&P 500 Hit Record Highs; Guardant, Intuitive Surgical, Incyte In Focus - Investor's Business Daily
Incyte: Maintaining Buy Rating As Hem/Oncology Portfolio Adds 2 Recent Wins (NASDAQ:INCY) - Seeking Alpha
INCY's Phase III Monjuvi Study Meets Key Goals in First-Line Lymphoma - Finviz
Incyte (NASDAQ:INCY) Price Target Raised to $94.00 - MarketBeat
Incyte reports positive results in late stage trial of lymphoma drug - Delaware Business Now
Positive top-line results for Incyte’s tafasitamab in DLBCL - The Pharma Letter
Incyte stock rises as Stifel reiterates Buy rating on positive trial data - Investing.com India
Why Is Incyte Stock Gaining Monday?Incyte (NASDAQ:INCY) - Benzinga
Incyte's blood cancer therapy slows disease progression in trial - Reuters
The Bull Case For Incyte (INCY) Could Change Following Positive frontMIND Phase 3 DLBCL Results - simplywall.st
Incyte (INCY) Achieves Phase 3 Success with Tafasitamab in Lymph - GuruFocus
Incyte marks late-stage trial win for Xencor-partnered lymphoma therapy - Seeking Alpha
Incyte (INCY) Achieves Key Milestones in Phase 3 Lymphoma Study - GuruFocus
Incyte’s tafasitamab meets primary endpoint in frontMIND trial By Investing.com - Investing.com Australia
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma - Yahoo Finance
Incyte Corp (NASDAQ:INCY) Shows High-Growth Momentum and Strong Technical Trend - Chartmill
Financiere des Professionnels Fonds d investissement inc. Invests $1.48 Million in Incyte Corporation $INCY - MarketBeat
Incyte Corp. Stock Outperforms Competitors On Strong Trading Day - 富途牛牛
INCYTE CORPORATION CMNRo Khanna Congressional Trade on May. 02, 2017 - Quiver Quantitative
Incyte takes JPMorgan stage as investors look for pipeline signals - MSN
Incyte Takes JPMorgan Stage as Investors Look for Pipeline Signals - MyChesCo
Incyte Corporation (NASDAQ:INCY) Receives Average Rating of "Hold" from Analysts - MarketBeat
Europe Approves Incyte’s Dual-Target Lymphoma Therapy, Expanding Options - MyChesCo
22,200 Shares in Incyte Corporation $INCY Purchased by Burney Co. - MarketBeat
Incyte Corporation (INCY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Pacer Advisors Inc. Grows Position in Incyte Corporation $INCY - MarketBeat
Swedbank AB Decreases Stock Holdings in Incyte Corporation $INCY - MarketBeat
Is It Too Late To Consider Incyte After A 45% Rally In 2025? - Yahoo Finance
Incyte Board Exit Closes an Era for the Biotech’s Longtime Leader - MyChesCo
Incyte Corporation Stock Live Price, Chart, Analysis, News & Forecast – Buy, Sell & Trade US Equities Today - livemint.com
Incyte (INCY) Valuation Check After Japan Oncology Approvals for Minjuvi and Zynyz - simplywall.st
The Bull Case For Incyte (INCY) Could Change Following New Minjuvi And Zynyz Approvals In Europe And Japan - Yahoo Finance
Thomas Tray Sells 600 Shares of Incyte (NASDAQ:INCY) Stock - MarketBeat
Incyte (NASDAQ:INCY) Insider Sells $277,400.00 in Stock - MarketBeat
Incyte principal accounting officer Tray Thomas sells shares worth $336k - Investing.com
Incyte Corp Principal Accounting Officer Sells Shares - TradingView — Track All Markets
Incyte Corp. stock underperforms Monday when compared to competitors - MarketWatch
Incyte (NASDAQ:INCY) Stock Price Down 3.4%Time to Sell? - MarketBeat
Incyte Secures Dual Approvals In Japan For Zynyz And Minjuvi - RTTNews
Incyte (INCY) Soars 5.5%: Is Further Upside Left in the Stock? - Yahoo Finance
Japan Approves Incyte’s (NASDAQ:INCY) Zynyz for First-Line Anal Cancer - Kalkine Media
Incyte Corp Azioni (INCY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.56%
0.80%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):